Combination therapies for treating cancer
Provided are methods for treating cancer in a patient by administering at least antibiotic selected from the group consisting of clofazimine, rifabutin and clarithromycin, in combination with an aryladamantane compound. In an embodiment, the aryladamantane compound is [3-(4-chlorophenyl)-adamantane-1-carboxylic acid (pyridin-4-ylmethyl)amide], or a pharmaceutically acceptable salt thereof.
1. A combination comprising:
(i) a compound of Structure (I)
or a pharmaceutically acceptable salt thereof; and
(ii) a compound of Structure (II)
or a pharmaceutically acceptable salt thereof.
2. The combination of claim 1 further comprising a compound of Structure (III)
or a pharmaceutically acceptable salt thereof.
3. The combination of claim 1 further comprising a compound of Structure (IV):
or a pharmaceutically acceptable salt thereof.
4. A method for treating cancer, or preventing cancer recurrence or progression in a human in need thereof, the method comprising administering to a human, concurrently or sequentially, a therapeutically effective amount of
(i) at least one antibiotic; and
(ii) an aryladamantane compound, wherein the aryladamantane compound is [3-(4-chlorophenyl)-adamantane-1-carboxylic acid (pyridin-4-ylmethyl)amide].
5. The method of claim wherein the at least one antibiotic and the aryladamantane compound are administered concurrently.
6. The method of claim wherein 4 , the at least one antibiotic and the aryladamantane compound are administered sequentially.
7. The method of claim 4 , wherein the at least one antibiotic is selected from the group consisting of clofazimine, clarithromycin and rifabutin.
8. The method of claim 4 , wherein the cancer is a solid tumor.
9. The method of claim 8 , wherein the solid tumor is selected from the group consisting of: lung carcinoma, lung metastasis, colon carcinoma and pancreatic ductal adenocarcinoma.
10. The method of claim 4 further comprising administering an antineoplastic agent to the human.
11. The method of claim 4 further comprising administering an immunomodulator to the human.
12. The method of claim 4 further comprising administering an immune checkpoint inhibitor to the human.
13. The method of claim 4 further comprising administering a matrix metalloproteinase inhibitor to the human.
14. A method of inhibiting the growth or proliferation of cancer cells in a cancer comprising
contacting cancer cells with an effective amount of at least one antibiotic and an effective amount of an aryladamantane compound, wherein the aryladamantane compound is [3-(4-chlorophenyl)-adamantane-1-carboxylic acid (pyridin-4-ylmethyl)amide],
thereby inhibiting the growth or proliferation of the cancer cells.
15. The method of claim 14 , wherein the cancer cells are pancreatic cancer cells.
16. The method of claim 14 , wherein the at least one antibiotic is selected from the group consisting of clofazimine, clarithromycin, and rifabutin.
17. The method of claim 14 , wherein an in vitro cell proliferation assay is used to measure metabolic activity of the cancer cells.